Ceftazidime
A third-generation parenteral cephalosporin antibiotic with potent activity against Pseudomonas aeruginosa and other gram-negative pathogens, used for serious hospital-acquired infections including pneumonia, bacteremia, and meningitis. It is a cornerstone antibiotic in treating gram-negative infections in immunocompromised patients. Resistance can emerge, and susceptibility testing is recommended.
Peso Molecular
546,6000 g/mol
LogP
0,40
TPSA
245,00 Ų
Regra dos 5 de Lipinski
Reprovado
Áreas Terapêuticas
Mecanismo de Ação
Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.
Estrutura 2D
Cite this structure
Embed this structure
SMILES
CC(C)(O/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)[O-])=C(C[n+]3ccccc3)CS[C@H]12)c1csc(N)n1)C(=O)O
InChI
InChI=1S/C22H22N6O7S2/c1-22(2,20(33)34)35-26-13(12-10-37-21(23)24-12)16(29)25-14-17(30)28-15(19(31)32)11(9-36-18(14)28)8-27-6-4-3-5-7-27/h3-7,10,14,18H,8-9H2,1-2H3,(H4-,23,24,25,29,31,32,33,34)/b26-13-/t14-,18-/m1/s1
Molecular Formula
C22H22N6O7S2
HBD / HBA
3 / 12
Ligações Rotacionáveis
8
Átomos Pesados
37
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Perguntas frequentes
A third-generation parenteral cephalosporin antibiotic with potent activity against Pseudomonas aeruginosa and other gram-negative pathogens, used for serious hospital-acquired infections including pneumonia, bacteremia, and meningitis. It is a cornerstone antibiotic in treating gram-negative infections in immunocompromised patients. Resistance can emerge, and susceptibility testing is recommended.
Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.
Yes, Ceftazidime is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL44354. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 5481173. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="ceftazidime"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/ceftazidime/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/ceftazidime/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/ceftazidime/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="ceftazidime"></drugfyi-drug>